{"id":"NCT01228747","sponsor":"UCB Japan Co. Ltd.","briefTitle":"A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)","officialTitle":"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With Generalized Tonic-clonic (GTC) Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2014-04","completion":"2014-05","firstPosted":"2010-10-26","resultsPosted":"2015-05-13","lastUpdate":"2025-04-03"},"enrollment":361,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Generalized Tonic-Clonic Seizures"],"interventions":[{"type":"DRUG","name":"Levetiracetam","otherNames":["Keppra®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Levetiracetam","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and tolerability of levetiracetam treatment used as adjunctive therapy in Japanese and Chinese epilepsy patients aged ≥16 years and with uncontrolled Generalized Tonic-Clonic seizures despite treatment with 1 or 2 anti-epileptic drugs.","primaryOutcome":{"measure":"Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation Periods)","timeFrame":"From Baseline to Week 28","effectByArm":[{"arm":"Placebo","deltaMin":-13.19,"sd":55.54},{"arm":"Levetiracetam","deltaMin":-68.22,"sd":34.95}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":58,"countries":["China","Japan"]},"refs":{"pmids":["30525116"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":125},"commonTop":["Nasopharyngitis","Dizziness","Pyrexia","Platelet count decreased","Protein urine present"]}}